DRKS00000812已完成不适用
AFP - L3% and DCP as tumor markers in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolisation (TACE)
KL Freiburg, Med. Klinik II0 个研究点目标入组 85 人开始时间: 2011年5月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 85
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •age between 18 and 80
- •- diagnosis of HCC according the AASLD criteria
- •- TACE is planned
- •- resection is impossible
排除标准
- •- liver tumor of unknown origin
- •- other liver tumors
- •- TACE is impossible
研究者
相似试验
已完成
不适用
Circulating tumor cells as a diagnostic marker for pancreatico-biliary malignanciesPancreatico-biliary malignanciesJPRN-UMIN000029808Fukushima Medical University School of Medicine22
尚未招募
不适用
Detection of prognostic biomarkers in patients with oral squamous cell carcinoma with tissue microarrayOral Squamous Cell CarcinomaC01C02C03C04C05C06Malignant neoplasm of base of tongueMalignant neoplasm of other and unspecified parts of tongueMalignant neoplasm of gumMalignant neoplasm of floor of mouthMalignant neoplasm of palateMalignant neoplasm of other and unspecified parts of mouthDRKS00010431niversitätsklinikum Hamburg-Eppendorf1,000
进行中（未招募）
1 期
A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung CancerEUCTR2017-003134-85-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.318
进行中（未招募）
1 期
A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung CancerTreatment of advanced NSCLCMedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003134-85-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.192
进行中（未招募）
1 期
A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung CancerTreatment of advanced NSCLCMedDRA version: 21.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003134-85-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.318